Title Physician

Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

NCT ID : 05812807
Protocol Number : A012103
Phase : 3
Location : Saint John's Cancer Institute
Parvin Peddi, M.D.

Known Metastatic Breast Cancer with ER-Positive and HER2-Negative Primary Lesions

NCT ID : 05068726
Protocol Number : GE-280-401
Phase : 4
Location : Saint John's Cancer Institute
Parvin Peddi, M.D.

Biomarker Low Risk Node Positive Breast Cancer: TAILOR RT.

NCT ID : 03488693
Protocol Number : CCTGMA.39
Phase : 3
Location : Santa Monica, CA
Janie Grumley, M.D.

Unresectable, Locally Advanced or Metastatic Triple-Negative Breast Cancer

NCT ID : 04958785
Protocol Number : GS-US-586-6144
Phase : 2
Location : Saint John's Cancer Institute
Parvin Peddi, M.D.

Monitoring Symptoms to Help Young Women Take Hormone Therapy for Stage I-III Breast Cancer, ASPEN Study

NCT ID : 05568472
Protocol Number : SWOG-S2010
Phase : 3
Location : Saint John's Cancer Institute
Janie Grumley, M.D.

A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy (Astefania)

NCT ID : 04873362
Protocol Number : WO42633
Phase : 3
Location : Disney Family Cancer Center
Erwin Grussie, M.D.